Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.

Abstract excerpt

PURPOSE: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the standard therapy for advanced lung adenocarcinomas with common EGFR mutations. However, the efficacy of EGFR-TKIs in patients with uncommon EGFR mutations (other than exon 19 deletions or exon 21 L858R mutation) remains undetermined. METHODS: Seven hundred and fifty-five non-small cell lung cancer (NSCLC) patients with EGFR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Carcinoma, Non-Small-Cell Lung